Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Isabelle Luquet

Showing results (31-40 of 61) with videos related to

Pageof 7
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 19, 2010
Addition of lomustine to idarubicin and cytarabine improves the outcome of elderly patients with de novo acute myeloid leukemia: a report from the GOELAMSArnaud Pigneux, Jean-Luc Harousseau, Francis Witz, et al.
Haematologica|March 10, 2018
Dexamethasone in hyperleukocytic acute myeloid leukemiaSarah Bertoli, Muriel Picard, Emilie Bérard, et al.
Cancers|March 29, 2020
Outcome of Relapsed or Refractory <i>FLT3</i>-Mutated Acute Myeloid Leukemia Before Second-Generation FLT3 Tyrosine Kinase Inhibitors: A Toulouse-Bordeaux DATAML Registry StudySarah Bertoli, Pierre-Yves Dumas, Emilie Bérard, et al.
Genes, Chromosomes & Cancer|November 22, 2022
The presence of a chromosomal abnormality in cytopenia without dysplasia identifies a category of high-risk clonal cytopenia of unknown significanceVictor-Emmanuel Brett, Nicolas Lechevalier, Franck Trimoreau, et al.
Blood|May 31, 2011
Dismal prognostic value of monosomal karyotype in elderly patients with acute myeloid leukemia: a GOELAMS study of 186 patients with unfavorable cytogenetic abnormalitiesAurore Perrot, Isabelle Luquet, Arnaud Pigneux, et al.
The Journal of Experimental Medicine|November 6, 2023
Stem cell-like reprogramming is required for leukemia-initiating activity in B-ALLVincent Fregona, Manon Bayet, Mathieu Bouttier, et al.
Haematologica|August 27, 2013
Prognostic impact of day 15 blast clearance in risk-adapted remission induction chemotherapy for younger patients with acute myeloid leukemia: long-term results of the multicenter prospective LAM-2001 trial by the GOELAMS study groupSarah Bertoli, Pierre Bories, Marie C Béné, et al.
Blood Advances|August 14, 2020
Delivering HDAC over 3 or 5 days as consolidation in AML impacts health care resource consumption but not outcomePierre-Yves Dumas, Sarah Bertoli, Emilie Bérard, et al.
Blood Cancer Journal|May 31, 2024
Imatinib with intensive chemotherapy in AML with t(9;22)(q34.1;q11.2)/BCR::ABL1. A DATAML registry studyCamille Gondran, Pierre-Yves Dumas, Emilie Bérard, et al.
Blood|January 17, 2013
Hyperdiploidy with 58-66 chromosomes in childhood B-acute lymphoblastic leukemia is highly curable: 58951 CLG-EORTC resultsNicole Dastugue, Stefan Suciu, Geneviève Plat, et al.
Pageof 7

Showing results (31-40 of 61) with videos related to

Sort By:
Pageof 7
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 19, 2010
Addition of lomustine to idarubicin and cytarabine improves the outcome of elderly patients with de novo acute myeloid leukemia: a report from the GOELAMSArnaud Pigneux, Jean-Luc Harousseau, Francis Witz, et al.
Haematologica|March 10, 2018
Dexamethasone in hyperleukocytic acute myeloid leukemiaSarah Bertoli, Muriel Picard, Emilie Bérard, et al.
Cancers|March 29, 2020
Outcome of Relapsed or Refractory <i>FLT3</i>-Mutated Acute Myeloid Leukemia Before Second-Generation FLT3 Tyrosine Kinase Inhibitors: A Toulouse-Bordeaux DATAML Registry StudySarah Bertoli, Pierre-Yves Dumas, Emilie Bérard, et al.
Genes, Chromosomes & Cancer|November 22, 2022
The presence of a chromosomal abnormality in cytopenia without dysplasia identifies a category of high-risk clonal cytopenia of unknown significanceVictor-Emmanuel Brett, Nicolas Lechevalier, Franck Trimoreau, et al.
Blood|May 31, 2011
Dismal prognostic value of monosomal karyotype in elderly patients with acute myeloid leukemia: a GOELAMS study of 186 patients with unfavorable cytogenetic abnormalitiesAurore Perrot, Isabelle Luquet, Arnaud Pigneux, et al.
The Journal of Experimental Medicine|November 6, 2023
Stem cell-like reprogramming is required for leukemia-initiating activity in B-ALLVincent Fregona, Manon Bayet, Mathieu Bouttier, et al.
Haematologica|August 27, 2013
Prognostic impact of day 15 blast clearance in risk-adapted remission induction chemotherapy for younger patients with acute myeloid leukemia: long-term results of the multicenter prospective LAM-2001 trial by the GOELAMS study groupSarah Bertoli, Pierre Bories, Marie C Béné, et al.
Blood Advances|August 14, 2020
Delivering HDAC over 3 or 5 days as consolidation in AML impacts health care resource consumption but not outcomePierre-Yves Dumas, Sarah Bertoli, Emilie Bérard, et al.
Blood Cancer Journal|May 31, 2024
Imatinib with intensive chemotherapy in AML with t(9;22)(q34.1;q11.2)/BCR::ABL1. A DATAML registry studyCamille Gondran, Pierre-Yves Dumas, Emilie Bérard, et al.
Blood|January 17, 2013
Hyperdiploidy with 58-66 chromosomes in childhood B-acute lymphoblastic leukemia is highly curable: 58951 CLG-EORTC resultsNicole Dastugue, Stefan Suciu, Geneviève Plat, et al.
Pageof 7